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214Promising Progression-Free Survival for Patients Low
and Intermediate Grade Lymphoid Malignancies after
Nonmyeloablative Umbilical Cord Blood
Transplantation
Claudio G. Brunstein,1,2 Susana Cantero,1 Qing Cao,1,3 Navneet Majhail,1,2
Brian McClune,1,2 Linda J. Burns,1,2 Marcie Tomblyn,1,2 Jeffrey S. Miller,1,2
Bruce R. Blazar,1,3 Philip B. McGlave,1,2 Daniel J. Weisdorf,1,2 John E. Wagner1,3Nonmyeloablative hematopoietic cell transplantation (HCT) has been used to treat patients with advanced
or high-risk lymphoid malignancies. We studied 65 patients (median age 46 years) receiving an umbilical cord
blood (UCB) graft after a single conditioning regimen consisting of cyclophosphamide (50 mg/kg) on day26,
fludarabine (40 mg/m2) daily on days26 to22, as well as a single fraction of total-body irradiation (TBI) (200
cGy) along with cyclosporine mycophenolate mofetil immunosuppression. Median time to neutrophil and
platelet recovery was 7.5 days (range: 0-32) and 46 days (range: 8-111), respectively. Cumulative incidences
of grade II-IV, grade III-IV acute, and chronic graft-versus-host disease (aGVHD, cGVHD) were 57% (95%
confidence interval [CI]: 43%-70%), 25% (95% CI: 14%-35%), and 19% (95% CI: 9%-29%), respectively.
Transplant-related mortality at 3 years was 15% (95% CI: 5%-26%). Median follow-up was 23 months. The
progression free-survival (PFS), current PFS and overall survival (OS) were 34% (95% CI: 21%-47%), 49%
(95% CI: 36%-62%), and 55% (95% CI: 42%-70%) at 3 years. Based on our data, we conclude that a nonmye-
loablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with
advanced lymphoid malignancies who lack a suitable sibling donor.
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Nonmyeloablative hematopoietic cell transplanta-
tion (HCT) has been increasingly utilized in patients
with advanced age, preexisting comorbidities, or those
patients previously treated with extensive alkylator-
based chemotherapy or autologous transplantation
[1-24]. These demographics are commonly seen in pa-
tients with advanced lymphoid malignancies, such as
follicular anddiffuse large-cell lymphoma, chronic lym-
phocytic leukemia, and Hodgkin lymphoma [8-23]. In
addition, low- and intermediate-grade lymphoidmalig-
nancies are more often diagnosed in the fifth and sixth1University of Minnesota Blood and Marrow Transplant
am; 2Divisions of Medical; and 3Pediatric Hematology,
logy and Transplantation, Minneapolis, Minnesota.
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6/j.bbmt.2008.11.013decade of life. A critical need, therefore, exists to iden-
tify new strategies to treat this patient population.
Depending on their ethnic background, 40%-80%
of thepatientswill notbe able tofindanacceptable adult
stemcell donor.As a result, umbilical cordblood (UCB)
has been increasingly used as an alternative source of
stem cells for nonmyeloablative transplantation [1-7].
We have previously reported on the feasibility of non-
myeloablative UCB transplantation for adult patients
with advanced hematologic diseases [1,7,25]. However,
there is still limited data on the efficacy of nonmyeloa-
blativeUCB transplantation for patients with lymphoid
malignancies [23]. Here, we report the outcomes of 65
patients with low- or intermediate-grade lymphoid
malignancies who underwent nonmyeloablative condi-
tioning followed by UCB transplantation at our center
between October 2001 and December 2006.PATIENTS AND METHODS
Patients
This is study included patients who had confirmed
histologic diagnoses of follicular small lymphoma
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phocytic leukemia (n 5 9), mantle-cell lymphoma (n
5 8), large-cell B cell lymphoma (n 5 11), anaplastic
T cell lymphoma (n5 2), peripheral T cell lymphoma,
unspecified (n 5 1), and Hodgkin’s lymphoma (n 5
23), and were eligible for UCB transplantation because
they had no suitably matched related donor. Advanced
disease was defined as disease failing at least 3 prior
treatment regimens or autologous transplantation.
High-risk disease was defined based on poor prognos-
tic factors present at diagnosis. Thirty-eight patients
have been previously reported in studies with different
focus by our group [1,7,25-27].
The eligibility criteria for nonmyeloablative UCB
transplantation has been previously described [1,7]. In
summary, patients were eligible for nonmyeloablative
therapy if they met any of the following criteria: age
$45 years, preexisting high-risk clinical features for
treatment-related mortality (TRM) defined as serious
organ dysfunction, invasive mold infection within 4
months prior to transplantation, Karnofsky Perfor-
mance score#80, or history of extensive prior therapy
(defined as$12months of alkylator-based chemother-
apy, $6 months alkylator-based chemotherapy plus
extensive radiation, or history of autologous transplan-
tation). Serious organ dysfunction was defined as: a hy-
perbilirubinemia .2 times the upper limit of normal,
elevated hepatic transaminases .2 times the upper
limit of normal, corrected carbon monoxide diffusing
capacity (DLCO)#50% of predicted, or left ventricu-
lar ejection fraction (LVEF) \45%. Patients .70
years of age or having end-stage organ dysfunction
(DLCO .30% predicted or LVEF \35%), active
serious infection, or human-immunodeficiency virus
infection were not eligible. Patients preexisting co-
morbidities were scored according to the Hematopoi-
etic Cell Transplant-Specific Comorbidity Index
(HCT-CI) [28]. The patients reported in this study
were treated in sequential protocols that were ap-
proved by the institutional review board of the Univer-
sity of Minnesota and registered at http://www.
clinicaltrials.gov as NCT00365287 (closed) and
NCT00305682. All patients or legal guardians pro-
vided written informed consent in accordance to the
Declaration of Helsinki prior to enrollment.UCB Unit Selection Algorithm
As previously described [1], UCB units were
required to be matched at$4 of 6 HLA antigens based
on antigen-level HLA-A and B and allele-level
HLA-DRB1 typing. Matching at HLA-C, DQ, and
DP were not considered. Target cell dose was $3.0
 107 total nucleated cell (TNC)/kg, resulting in the
selection of a second partially HLA matched UCB
unit in 86% of the patients. In patients for whom a sec-
ond UCB unit could be identified, the second unit hadto be matched at$4 of 6 HLA antigens to the patient,
as well as the first unit. Both units were required to
have $1.5  107 TNC/kg. Over the duration of the
study, single UCB unit grafts were required to have
a minimum cryopreserved TNC dose $2.0  107/
kg. ABO blood type matching was not considered in
UCB unit selection [1,7].
Treatment
Preparative regimen and graft-versus-host
disease (GVHD) prophylaxis
All patients received a single dose of cyclophospha-
mide (CY) 50 mg/kg on day 26 intravenously (i.v.),
fludarabine (FLU) 40 mg/m2 i.v. daily on days 26 to
22, and a single fraction of total-body irradiation
(TBI) 200 cGy without shielding on day 21, as previ-
ously described [1]. Equine antithymocyte globulin
(ATG, ATGAM, Pharmacia, Kalamazoo, MI) at 15
mg/kg every 12 hours i.v. on days26 to24 was added
in a subpopulation of patients (n5 7) who had received
\2 cycles of multiagent chemotherapy within the 3
months prior to enrollment and who had no history
of autologous transplantation. Immunosuppression
consisted of mycophenolate mofetil (MMF) at 1 g in-
travenously or orally twice or thrice daily from day
23 to 130, as well as cyclosporine (CsA) twice daily
starting on day 23 and continuing for at least 6
months, with target trough levels of 200-400 ng/mL.
UCB Transplantation
Units were thawed using the method described by
Rubinstein et al. [29]. On day zero, UCB units were in-
fused after washing. In recipients of 2 partially HLA-
matched units, infusion of the second unit was started
as soon as the first unit was completely infused. The
order of infusion was random, and not based on
HLA matching or cell dose. Supportive care has
been previously described [1,30].
Study Endpoints
The primary endpoint was progression-free sur-
vival (PFS). Secondary endpoints included the inci-
dence of neutrophil recovery (defined as absolute
neutrophil count [ANC] $500/mL by 42 days after
transplantation), wholemarrow chimerism (partial chi-
merism was defined as marrow reconstitution of 10%-
90% donor cells, and complete chimerism was defined
as.90%as the level of accuracy in our chimerism lab is
65%), unsupported platelet recovery$50,000/mL at 6
months, acute GVHD (aGVHD) at day 100, chronic
GVHD (cGVHD) at 1 year, presence of disease at 3
years, TRM at 3 years and overall survival (OS) at 3
years.We also performed an exploratory analysis to es-
timate the impact of the treatment of posttransplant re-
lapse withmanipulation of immunosuppression and/or
216 Biol Blood Marrow Transplant 15:214-222, 2009C. G. Brunstein et al.chemotherapy and/or radiation therapy. For this pur-
pose, patients who were progression-free since trans-
plant plus patients who had relapsed or progressed
after transplant but had achieved a second complete re-
mission following intervention were included in amul-
tistate model approach to calculate the current PFS
[31]. Current event times for neutrophil recovery
were measured from the date of transplantation and
were censored for death or disease progression before
day 21 without neutrophil recovery. Primary graft fail-
ure was defined as lack of neutrophil recovery (ANC
$500/mL) at day 42 or\10% marrow reconstitution
of donor origin. Secondary graft failure was defined
as severe neutropenia of .1 week duration without
other etiology or autologous recovery after primary en-
graftment. Diagnosis of aGVHD and cGVHD was
based on standard clinical criteria with histopathologic
confirmation where possible [32].Table 1. Patient and Graft Characteristics
Number of patients 65
Age in years, median (range) 46 (6-68)
Weight in kilograms, median (range) 80.8 (22.1-124.3)
Male 40 (61%)
Recipient CMV positive 27 (42%)
Histology
Follicular lymphoma/CLL 20 (31%)
Large cell/mantle cell lymphoma 22 (34%)
Hodgkin’s lymphoma 23 (35%)
Pretransplant hematologic function
White blood cell count, median (range) 5500  109/L (0.3-24)
Absolute neutrophil count, median (range) 3600  109/L (0.2-15)
Platelet count, median (range) 171  109/L (13-422)
Number of UCB units in the graft
One UCB unit 9 (14%)
Two UCB units 56 (86%)
HLA matching to recipients
6/6 or 6/6 + 6/6 3 (5%)
6/6 + 5/6 3 (5%)
5/6 or 5/6 + 5/6 14 (21%)
5/6 + 4/6 20 (31%)
4/6 or 4/6 + 4/6 25 (38%)
Sex match (donor-recipient)*
Matching 19 (29%)
Mismatching 46 (71%)
ABO blood type (donor-recipient)*
Matched 10 (15%)
Mismatched 54 (83%)
Missing 1 (2%)
Total nucleated cell dose (107/kg), median
(range)
3.3 (2.0-6.2)
CD34+ cell dose (105/kg), median (range) 4.4 (0.7-14.3)
CD3+ cell dose (107/kg), median (range) 1.4 (0.4-3.0)
CMV indicates cytomegalovirus; CLL, chronic lymphocytic leukemia;
UCB umbilical cord blood; HLA, human leukocyte antigen; kg, kilogram.
*For recipients of twoUCB units were consideredmismatched if at least
one of the units was mismatched.Statistical Analysis
For the purpose population description and analy-
sis, patients were grouped with follicular small lym-
phoma and chronic lymphocytic leukemia (CLL) as
follicular lymphoma/CLL, and those mantle-cell lym-
phoma, large-cell B cell lymphoma, anaplastic T cell
lymphoma, and peripheral T cell lymphoma, unspeci-
fied as large-cell/mantle-cell lymphomas. Hodgkin’s
lymphoma (HL) patients were their own group.
Chemotherapy-sensitive disease was defined as pa-
tients in complete remission (CR), partial remission
(PR), and minimal response. Resistant disease was
defined as progressive disease and disease with stable
tumor size since the last chemotherapy regimen.
Current PFS was calculated using a multistate model
approach [31]. For current PFS analyses, relapse, pro-
gression and death were considered events. Variables
related to patient, disease, and transplant characteris-
tics were compared using the chi-square test for cate-
goric variables and the Kruskal-Wallis test for
continuous variables. Probabilities of OS and PFS
were calculated using the Kaplan-Meier estimator
[33]. For the purposes of survival analyses, death
because of any cause was considered an event. Early
deaths were counted as events. Data on surviving pa-
tients were censored at last follow-up for analyses of
current PFS. Patients alive and in remission were cen-
sored at last follow-up. The cumulative incidence
function was used to calculate probabilities and 95%
confidence intervals (CI) of neutrophil and platelet re-
covery, aGVHD and cGVHD,TRM, and relapse [33].
For analyses of neutrophil and platelet recovery and
GVHD, death without the event was the competing
hazard. For TRM or relapse analyses, the competing
event was relapse or TRM, respectively.
Statistical comparison of time-to-event curves was
completed by a log-rank test. Continuous factors,such as chimerism and cell dose, were compared be-
tween recipients of 1 and 2 units using the nonparamet-
ric Wilcoxon test [34]. Comparison of proportions was
performed by the chi-square test or Fisher’s exact test if
the expected number was#5. Multivariate analysis was
not performed because of the small number of patients.RESULTS
Patients and Disease Characteristics
Between October 2001 and December 2006, 65
consecutive patients with low- and intermediate-grade
lymphoid malignancies were treated with nonmyeloa-
blative UCB transplantation at the University of
Minnesota. Patient and graft characteristics are sum-
marized in Table 1. Sixty-one percent of patients
were male, with a median age of 46 years and median
weight of 81 kg. Eight of 35 patients who were $45
years of age who received a nonmyeloablative condi-
tioning solely based on the age criteria. The median
Karnofsky score at the time of transplantation was 90
(range: 70-100), with 3 patients being below 80. The
HCT-CIwas zero in 5, 1-2 in 18, and$3 in 27 patients.
In 15 patients therewas not enough information for the
Biol Blood Marrow Transplant 15:214-222, 2009 217Nonmyeloablative UCB Transplantation for Lymphoid MalignanciesHCT-CI score to be calculated. Median infused TNC
dose was 3.3 107/kg. Median CD341 and CD31 cell
doses were 4.4 105/kg and 1.4 107/kg, respectively.
Disease characteristics and treatment prior to
UCB transplantation are summarized in Table 2.
Patients received a median of 4 (range: 1-9) prior
treatment regimens before UCB transplantation.
Forty-nine patients had received $3 prior treatment
regimens. A majority of patients had chemotherapy-
sensitive disease (82%) and normal LDH (normal
range: 325-750 u/L) (66%) at transplantation with
no significant difference among diagnostic subgroups.
HL patients received a higher proportion of prior ra-
diation therapy (65%) and autologous transplantation
(78%), compared to follicular lymphoma/CLL and
large-cell/mantle-cell lymphomas. The disease status
at the time of UCB transplantation for the follicular
lymphomas was CR in 1 patient, relapsed/persistent
with chemotherapy-sensitive disease in 8, and chemo-
therapy refractory disease in 2 patients. For patients
with Hodgkin’s lymphoma disease, status at the time
of UCB transplantation was CR in 6, relapsed/persis-
tent chemotherapy-sensitive disease in 15, and chemo-
therapy refractory in 2 patients. For patients with
large-cell lymphoma disease, status at the time of
UCB transplantation was CR in 2, relapsed/persistentTable 2. Disease Characteristics
Characteristics
Follicular
Lymphoma/ CLL
Number of patients 20
Chemosensitive*
Yes 13 (65%)
No 7 (35%)
Number total previous chemotherapy regimens,
median (range)
4 (2-9)
Bulky adenopathy*
Yes 2 (10%)
No 18 (90%)
Missing 0
Previous autologous hematopoietic stem cell transplantation
Yes 0
No 20 (100%)
Prior radiation therapy
Yes 5 (25%)
No 15 (75%)
Missing 0
Bone Marrow involvement*
Yes 8 (40%)
No 12 (60%)
Missing 0
LDH †
Abnormal 5 (25%)
Normal 15 (75%)
Extra-nodal disease †‡
Yes 3 (15%)
No 17 (85%)
CLL indicates chronic lymphocytic leukemia; LDH, lactate dehydrogenase.
*At the time of transplantation.
†At the time of diagnosis.
‡Extra-nodal sites involved were soft tissue or bone (n5 7); gastrointestinal (n
(n 5 1), pancreas (n 5 1), and central nervous system (n 5 1).chemotherapy-sensitive disease in 7, and chemother-
apy refractory in 5 patients. For patients with man-
tle-cell lymphoma disease, status at the time of UCB
transplantation was CR in 1, relapsed/persistent che-
motherapy-sensitive disease in 6, and chemotherapy
refractory in 1 patient. Last, for patients with CLL/
small lymphocytic lymphoma (SLL), the disease status
at the time of UCB transplantation was RAI stage 0 in
1, stage I in 3, stage III in 1, stage IV in 2, and primary
induction failure in 2 patients. At the time of trans-
plantation after receiving salvage therapy, the median
international prognostic index (FLIPI [35]) score was
2 (range: 1-3) for the follicular lymphoma patients,
and whereas for revised international prognostic index
for large-cell B cell lymphoma (R-IPI [36]) was
‘‘good’’ in 5, ‘‘very good’’ in 3, and not enough infor-
mation to calculate in 3 patients. Patients with large-
cell/mantle-cell lymphomas were more likely to have
extra-nodal involvement, whereas patients with follic-
ular lymphoma/CLL were more likely to have bone
marrow involvement. Thirteen patients with large-
cell lymphoma (n 5 7) and HL (n 5 6) underwent
an UCB transplant instead of autologous transplanta-
tion because of poor response to chemotherapy as evi-
denced by never achieving a CR or a remission of\6
months followed by poor response to chemotherapyLarge Cell/ Mantle
Cell Lymphomas
Hodgkin’s
Lymphoma P Value
22 23
18 (82%) 22 (96%) .07
4 (18%) 1 (4%)
3 (1-6) 4 (2-9) .03
2 (9%) 1 (4%) .31
18 (82%) 22 (96%)
2 (9%) 0
8 (36%) 18 (78%) <.01
14 (64%) 5 (22%)
7 (32%) 15 (65%) .03
15 (68%) 6 (26%)
0 2 (9%)
2 (9%) 0 <.01
20 (91%) 22 (96%)
0 1 (4%)
9 (41%) 8 (35%) .79
13 (59%) 15 (65%)
15 (68%) 8 (35%) <.01
7 (32%) 15 (65%)
5 6), lung (n5 5), skin (n5 3), salivary gland (n5 1), tonsils (n5 1); liver
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Figure 1. Cumulative incidence of relapse after nonmyeloablative UCB
transplantation for patients with follicular lymphoma/CLL (—), large-cell
/mantle-cell lymphoma (---), and HL (- - -).
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large-cell lymphoma in a patient with common vari-
able immunodeficiency (n 5 1).
Hematopoietic Recovery and Chimerism
The incidence of neutrophil recovery was 89%
(95% CI: 80%-98%) by day 42, with a median time
to neutrophil recovery of 7.5 days (range: 0-32). The
cumulative incidence of platelet recovery was 82%
(95% CI: 65%-98%) at 180 days, with a median time
to platelet recovery $50,000/mL of 46 days (range: 8-
111).Neutrophil recoverywas not influenced by the in-
fused TNC, CD34, or CD3 cell doses, sex, ABO or
HLAmatching, andby the pretransplantmarrowcellu-
larity, white blood cell, or neutrophil count. However,
the cumulative incidence of neutrophil recovery was
significantly higher for patients who had a platelet
count pretransplant above the median (97% [95% CI:
87%-100%] versus 91% [95% CI: 66%-92%], P 5
.03). Median time to platelet recovery was influenced
by the degree of HLAmatching. Patients who received
only 6 of 6 HLA-matched unit(s) had a median time to
platelet recovery of 37 days (range: 34-46), compared to
44.5 days (range: 8-83) and 48 days (range: 24-111) for
those who received at least 1 5 of 6 or 1 4of 6 HLA-
matched unit, respectively (P 5 .03).
Thirty patients (57%) had mixed chimerism (pres-
ence recipient and donor DNA) in the bone marrow at
day 21, but 97% had achieved full chimerism (only do-
nor DNA) by day 180. Among patients who received 2
UCBunits, 28%had both donor units detectable in the
bone marrow at day 21. As expected , all patients who
received 2 UCB units had complete chimerism (only
donor DNA) derived from a single UCB unit by 180
days.
Acute GVHD and cGVHD
The incidences of grade II-IV and grade III-IV
aGVHD at day 100 were 57% (95% CI: 43%-70%)
and 25% (95% CI: 14%-35%), respectively. The me-
dian time to the development of aGVHD was 37 days
and was not influenced by disease subgroups by the
CD3 cell dose. Twelve patients had cGVHD, for an in-
cidence of 19% at 24 months (95% CI: 9%-29%). In-
cidences of aGVHD and cGVHD were similar
between lymphoma subgroups and for those who did
or did not receive pretransplant ATG (data not shown).
TRM
TRM at 3 years was 15% (95% CI: 5%-26%) for
the whole cohort. TRM at 3 years for patients with
follicular lymphoma/CLL, large-cell/mantle-cell
lymphomas, and HL subgroups was 5% (95% CI:
0%-14%), 24% (95% CI: 4%-44%), and 13% (95%
CI: 0%-27%), respectively (P 5 .41). The TRM at 3
years for patients who had an HCT-CI score of0 was zero, 1-2 was 18% (95% CI: 0%-35%), and
$3 was 17% (95% CI: 0%-34%), and this difference
was not statistically significant (P 5 .46).
Relapse and PFS
At a median follow-up in surviving patients of 23
months, the cumulative incidence of relapse of 42%
(95% CI: 29%-56%) at 3 years. The cumulative inci-
dence of relapse for follicular lymphoma/CLL, large-
cell/mantle-cell lymphomas, and HL were 37%
(95% CI: 15%-58%), 45% (95% CI: 24%-67%),
and 43% (95%CI: 20%-66%), respectively (Figure 1).
The median time to progression was 90 (95% CI:
61%-119%) days and to relapse was 175 (95% CI:
119%-370%) days. The overall PFS was 34% (95%
CI: 21%-47%), and the PFS rates for follicular lym-
phoma/CLL, large-cell/mantle-cell lymphomas, and
HL were 50% (95% CI: 27%-72%), 24% (95% CI:
4%-44%), and 33% (95%CI: 12%-53%), respectively
(Figure 2).
Of the 26 patients who had disease progression or
relapsed, 15 were treated with posttransplantation
therapy (Table 3).The remaining 11 patients either de-
clined further therapy orwere clinically not suitable for
treatment intervention (ie, active aGVHD). Nine pa-
tients achieved CR, whereas the remaining 6 patients
progressed. The overall current PFS at 3 years was
49% (95% CI: 36%-62%). The current PFS rates for
follicular lymphoma/CLL, large-cell/mantle-cell lym-
phomas, andHLwere 68% (95%CI: 45%-85%), 47%
(95% CI: 26%-67%), and 46% (95% CI: 23%-68%),
respectively (Figure 3). The rise and fall of the current
PFS curves is because of successful induction ofCR fol-
lowing treatment intervention for relapse or disease
progression.
Survival
The median follow-up of the patients alive is 23
months (range: 3-62). The OS at 3 years was 55%
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Figure 2. PFS after nonmyeloablative UCB transplantation for patients
with follicular lymphoma/CLL (—), large-cell /mantle-cell lymphoma
(---), and HL (- - -).
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years for patients with follicular lymphoma/CLL,
large-cell/mantle-cell lymphomas, and HL were 69%
(95% CI: 48%-90%), 54% (95% CI: 33%-75%),
and 43% (5%CI: 18%-69%), respectively. The differ-
ence in OS among disease groups was not statistically
significant (P 5 .37). Further univariate analysis
showed survival was not influenced byHLA-matching,
CD341 cell dose, development of aGVHD, presence
of bulky tumor, chemotherapy sensitivity, LDH level,
prior autologous transplantation, prior radiation
therapy, presence of extra-nodal disease, bone marrow
involvement, or number of prior cycles of chemother-
apy. The median Karnofsky score of the surviving
patients both at 100 days and at 1 year was 90% (range:
90%-100%). The causes of death included disease
recurrent (n 5 14), multiple organ failure (n 5 4),
infection (n 5 4), respiratory insufficiency (n 5 3),
and other (n 5 3).DISCUSSION
Umbilical cord blood is an attractive alternative
source of HSC for transplantation as it is rapidly avail-
able, its ability to cross HLA barriers, and relatively
low incidence of GVHD if considered that most
UCB transplants are mismatched. Umbilical cord
blood has been the preferred source of unrelated
HSC for transplantation in our institution since the
early 2000s [1,7,30,37,38]. Some patients treated in
our institution were referred to our institution after
failing to find an unrelated donor after searching for
an extended period of time. Our strategy of UCB graft
selection was initiated in 2000 and allows for the utili-
zation of 2 UCB units to compose a graft allowed us to
find grafts for most adult patients [1,30]. This study
demonstrates that patients with lymphoid malignan-
cies treated with nonmyeloablative conditioning fol-
lowed by UCB transplantation have a low TRM,
with the added benefit that a sizable proportion ofthese patients enjoy prolonged PFS and OS. More-
over, despite the lack of donor lymphocytes, a propor-
tion of patients who relapse after nonmyeloablative
UCB transplantation may still be salvaged by manipu-
lation of immunosuppressive therapy with or without
additional chemotherapy or localized radiation ther-
apy.
In the present study, neutrophil and platelet recov-
ery was relatively rapid compared to other reports of
UCB transplantation after myeloablation [37,39,40].
The reason for this rapid hematologic recovery is the
nonmyeloablative intensity of our conditioning regi-
men that likely allows transient autologous reconstitu-
tion and a period of mixed chimerism. In our
population of heavily pretreated patients, 90% of the
patients had received chemotherapy within a few
weeks of undergoing nonmyeloablative conditioning
and 40% had received a prior autologous transplant;
both of these factors are associated with a decreased
risk of graft failure [1,41].
Consistent with previous reports by our group [1]
and others [3,23], we observed that approximately two-
thirds of patients developed grades II-IV aGVHD
after nonmyeloablative UCB transplantation. Other
studies, however, have reported incidences of aGVHD
below 40% after nonmyeloablative UCB transplanta-
tion.[2,4-6]. This lower incidence is possibly to differ-
ences in patient selection, HLA matching, and
posttransplantation immunosuppressive regimens. Al-
though studies involving adult donor stem cells for
lymphoid malignancies have reported an incidence of
aGVHD lower than that reported here, it is important
to note that alemtuzumab, an in vivo T cell depleting
agent, was frequently used as a part of the conditioning
regimen [9,13,17-19,22]. In our cohort we found no
predictors of the development of aGVHD.
The TRM incidence of 15% observed in this study
compares favorably with other series of nonmyeloabla-
tive transplantation that have reported rates of 10%-
45% for patients receiving UCB [2-6,23] or related
and unrelated adult donor stem cells [13,16,
18-20,22]. A lower TRM incidence has been associated
with a low incidence of aGVHD associated in series
that administered ATG [12,14] or alemtuzumab
[13,17,18] as part of the conditioning regimen. In
this cohort we found no predictors of TRM, including
the HCT-CI score, prior therapy or age.
In our study, one-third of the patients were free of
disease progression at 3 years. Similar studies of re-
lated and unrelated adult donor nonmyeloablative
HCT for patients with lymphoid malignancies report
a 2-4-year disease-free survival (DFS) rate between
30% and 50% [8,10,11,13,16,18-22]. After nonmye-
loablative related and unrelated donor HCT, up to
10%-30% of patients may receive a donor lymphocyte
infusion (DLI) as salvage therapy for persistent, re-
lapsed, or progressive disease [8,9,13,17,19]. Among
Table 3. Characteristics and Outcomes of 15 Patients Who Received Treatment for Relapse or Progression after Nonmyeloablative UCB Transplantation
Patient
Histological
Diagnosis
Disease Status
at UCBT
Number of
Prior
Therapies
Time to
Relapse/
Progression
(Days)
Time to acute
GVHD (Days)
Chimerism at
the Time
of Relapse/
Progression
Treatment at Relapse/
Progression
Time from
Relapse/ Progression
to Treatment (Months)
Response to
treatment Outcome
1 Diffuse large cell B cell Partial remission 3 104 19 100% taper immunosuppression*
+ rituximab†
<1 CR Alive
2 Diffuse large cell B cell Partial remission 3§ 6 51 82% taper immunosuppression*
+ rituximab†
<1 PROG Dead
3 Diffuse large cell B cell Partial remission 6 164 30 100% rituximab† 5 CR Alive
4 Diffuse large cell B cell Partial remission 3 120 31 100% taper immunosuppression*
+ rituximab†
5 CR Alive
5 Diffuse large cell B cell Partial remission 2§ 21 No 100% taper immunosuppression*
+ rituximab†
<1 PROG Dead
6 Diffuse large cell B cell Partial remission 2 21 63 NA rituximab† + radiotherapy¶ 3 PROG Dead
7 Diffuse large cell B cell Chemotherapy refractory 3 211 No 100% taper immunosuppression*
+ rituximab†
5 CR Alive
8 Mantle cell lymphoma Chemotherapy refractory 2§ 100 No 100% taper immunosuppression*
+ chemotherapy + radio-
immunotherapy
2 CR Alive
9 Large cell T cll Partial remission 2 90 35 97% radiotherapy 1 PROG Dead
10 Anaplastic T cell Partial remission 3 236 No 100% taper immunosuppression* <1 CR Alive
11 Follicular B cell Partial remission 8 55 72 91% rituximab† 6 CR Alive
12 Follicular B cell Complete remission 4 188 No 100% taper immunosuppression*
+ rituximab†
3 CR Alive
13 Follicular B cell Partial remission 4 42 67 100% taper immunosuppression* 1 PROG Dead
14 Hodgkin lymphoma Complete remission 4§ 106 No NA taper immunosuppression*
+ chemotherapy +
radiotherapy
18‡ CR Alive
15 Hodgkin lymphoma Partial remission 9 88 15 100% taper immunosuppression*
+ chemotherapy +
radiotherapy
6 PROG Dead
UCBT indicates umbilical cord blood transplantation; GVHD, graft-versus-host- disease; CR, complete remission; PROG, progression.
*Taper of cyclosporine A and/or steroids started one to four weeks of diagnosis of relapse/progression.
†Rituximab was dosed at 375 mg/m2/week for 4 weeks.
§Patient who underwent prior autologous transplant.
‡Interval to last salvage therapy
¶Palliative intent radiation therapy.
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Figure 3. Current PFS after nonmyeloablative UCB transplantation
for patients with follicular lymphoma/CLL (—), large-cell /mantle-cell
lymphoma (---), and HL (- - -).
Biol Blood Marrow Transplant 15:214-222, 2009 221Nonmyeloablative UCB Transplantation for Lymphoid Malignanciespatients receiving DLI, the response rate may be as
high as 70% [19], with 30%-50% achieving CR
[8,9,13,17,19].
Interestingly, 9 of 26 patients who had disease
progression or relapse in our cohort could be sal-
vaged by tapering immunosuppression, rituximab,
systemic chemotherapy, radiation therapy, or a com-
bination of these treatment strategies. Moreover, ev-
ery CR achieved in this setting resulted in a durable
outcome. Because these group of patients had
received a median of 3 (range: 3-9) prior treatment
regimens (Table 3), some had had a prior autologous
transplant (n 5 4), and most (n 5 11) were in partial
remission prior to UCB transplantation, we speculate
that the graft-versus-malignancy effect may have
been reestablished after posttransplantation treat-
ment and was contributing to the prolonged remis-
sions. This is reflected in the current PFS of 49%
at 3 years. The concept of current PFS was proposed
to calculate the PFS for patient with chronic myelog-
enous leukemia who were treated with DLI and were
restored to complete remission [31,42-44]. Recently,
Thomson et al. [24] reported a 42% current PFS for
patients with Hodgkin’s lymphoma who received
a matched related or unrelated donor transplant after
reduced-intensity conditioning (RIC). In this series
21 of 38 patient relapsed, and 8 of 15 patients who
received DLI responded, 7 with a CR; 3 later pro-
gressed. In our cohort CRs achieved after posttrans-
plant treatment were sustained. It is interesting that
the graft-versus-leukemia (GVL) effect may be rees-
tablished after nonmyeloablative transplantation by
manipulating the immune environment and/or che-
motherapy. This may be of particular importance
in the UCB setting where DLI is not available.
The durability of the responses obtained after ma-
nipulation of the immunosuppression and/or addi-
tional therapy for relapses and progressions after
UCB transplantation will be better determined by
longer follow-up and larger numbers of patients.In conclusion, nonmyeloablative UCB transplan-
tation for patients with low- and intermediate-grade
lymphoid malignancies is associated with low TRM
and encouraging current PFS. Despite the unavailabil-
ity of DLI, it is still possibly to salvage a significant
proportion of patients and provide long-term remis-
sions by manipulating immunosuppression and/or
additional systemic or local therapy. Our study dem-
onstrates that nonmyeloablative UCB transplantation
extends transplantation therapy to a much larger num-
ber of patients.ACKNOWLEDGMENTS
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